Target trial emulates connecting GLP-1 receptor agonists use with acute pancreatitis risks in diabetes patients, indicating temporal risk patterns.
Key Points
To determine the association between glucagon-like peptide-1 receptor agonists and the risk of all cause and specific acute pancreatitis.
Target trial using electronic healthcare databases from the Veterans Affairs healthcare system.
Compared initiation of GLP-1RAs in 132,551 subjects versus sulfonylureas in 201,136 subjects.
Utilized discrete time survival models with inverse probability weighting.
No significant difference in all cause pancreatitis rates between GLP-1RA and sulfonylureas initiators after one year.
GLP-1RA was linked to higher risk of suspected drug induced pancreatitis early on, while reducing risks of hypertriglyceridaemia and alcohol induced pancreatitis later.
Drug induced pancreatitis risk peaked in the first three months, while reductions in other types varied across the year.